Search

Displaying results 1141 - 1150 of 10000 in total
  1. Drug

    Asenapine

    go.drugbank.com/drugs/DB06216
    ApprovedInvestigational

    Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with

    Products: SYCREST 5MG DILALTI TABLET, 100 TABLET, SYCREST 10MG DILALTI TABLET, 100 TABLET
  2. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.

    Synonyms: L-OrnithineMixtures: GNC PP L-Arginine L-Ornithine Tablet, PEDASEL %10 AMİNO ASİT ÇÖZELTİSİ, 100 ML
  3. Drug

    Letermovir

    go.drugbank.com/drugs/DB12070
    ApprovedInvestigational

    [L1021] It is the first of a new class of CMV anti-infectives called DNA terminase complex inhibitors.[A31290] Letermovir has recieved both priority and orphan drug status from the FDA.

    Products: PREVYMIS 240 MG SOLUCIÓN INYECTABLE, PREVYMİS 240 MG FİLM KAPLI TABLET, 28 ADET
  4. Drug

    Deflazacort

    go.drugbank.com/drugs/DB11921
    Approved

    Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD).

    Products: FLANTADIN 30 MG TABLET, 10 ADET, CLOBAK 6 MG
  5. Drug

    Dexchlorpheniramine maleate

    go.drugbank.com/drugs/DB09555
    Approved

    Dexchlorpheniramine is the S-enantiomer of chlorpheniramine which is a 1st generation anti-histamine.

    Mixtures: Rescon MX, HUFADEXTA-MProducts: POLARAX SYRUP 2 mg/5 ml, SOMIN TAB 2 mg
  6. Drug

    Selumetinib

    go.drugbank.com/drugs/DB11689
    ApprovedInvestigational

    [A193533] Following its initial FDA approval on April 10, 2020,[L49991] and Health Canada approval on August 23, 2022,[L49986] the regulatory landscape has evolved. … [A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications, including the development of multiple tumours in the nervous system

    Products: Koselugo Hard Capsules 10 mg, Koselugo Hard Capsules 25 mg
  7. Drug

    Alanyl glutamine

    go.drugbank.com/drugs/DB11876
    Investigational

    Alanyl Glutamine is under investigation in clinical trial NCT00338221 (Clinical Trial of Alanyl-Glutamine or Glycine in Children With Persistent Diarrhea or Malnutrition).

    Synonyms: L-Alanyl-L-glutamine, N(2)-L-Alanyl-L-glutamineProducts: Kipo for IV Infusion 200 mg/ml, DIPEPTIVEN 100 ML SOLUSYON
  8. Drug

    Duloxetine

    go.drugbank.com/drugs/DB00476
    ApprovedInvestigational

    Duloxetine is a dual serotonin and norepinephrine reuptake inhibitor.[label] It was originally discovered in 1993 and developed by Eli Lilly and Company as LY248686. … [L6454] It has since received approval for a variety of indications including the treatment of neuropathic pain, Generalized Anxiety disorder, osteoarthritis, and stress incontinence.

    Products: Duloxetin neuraxpharm 120 mg magensaftresistente Hartkapseln, DULOXETIN 1A PHARMA 20 MG
  9. Drug

    Telmisartan

    go.drugbank.com/drugs/DB00966
    ApprovedInvestigational

    blockers (ARBs) such as telmisartan bind to the angiotensin II type 1 (AT1) receptors with high affinity, causing inhibition of the action of angiotensin II on vascular smooth muscle, ultimately leading to a

    Mixtures: XIFEN A®80 /10 MG, TEMRED-A® TABLETAS 80 MG + 10 MG .Products: TELMISARTAN AL 40 MG TAB, TELMISARTAN AL 80 MG TAB
  10. Drug

    Tasimelteon

    go.drugbank.com/drugs/DB09071
    ApprovedInvestigational

    Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). … In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset.

    Products: Hetlioz LQ